Resumen: Background The relationship between tobacco and depressive symptoms has been examined. However, there is little information on the evolution of these symptoms when an individual quits. The aim of this study was to analyze the evolution of depressive symptoms over time (pre-, post-treatment, 1-, 3-, 6-, and 12-months follow-up) in relation to smoking status 12 months after having received a psychological treatment for smoking cessation. Method The sample was made up of 242 adults who received cognitive-behavioral treatment for smoking cessation (64.4% women; mean age=41.71 years). The BDI-II was used to assess depressive symptomatology. Participants were classified into three groups according to smoking status at 12-months follow-up (abstainers, relapsers, and smokers). Results There were no significant differences in depressive symptoms among the three groups at pretreatment. At the end of treatment, abstainers and relapsers presented less depressive symptomatology than smokers. At follow-up, abstainers continued to present less depressive symptomatology than smokers, whereas in relapsers, symptoms began to increase as the relapses occurred. Regarding the evolution of depressive symptomatology, the abstainer and relapser groups showed a significant reduction at the end of treatment. Only in the group of abstainers did the decrease continue during 12 months follow-up. Limitations The decrease of the initial sample size from 562 to 242 participants. Variables such as self-esteem and self-efficacy were not assessed. Conclusions Smoking cessation is associated with a decrease in depressive symptomatology, that is maintained over time. In contrast, relapse is associated with an increase of such symptoms. These findings signify the potential importance of addressing depressive symptomatology in smoking cessation treatment. Idioma: Inglés DOI: 10.1016/j.jad.2015.11.042 Año: 2016 Publicado en: Journal of Affective Disorders 191 (2016), 94-99 ISSN: 0165-0327 Factor impacto JCR: 3.432 (2016) Categ. JCR: PSYCHIATRY rank: 26 / 139 = 0.187 (2016) - Q1 - T1 Categ. JCR: CLINICAL NEUROLOGY rank: 55 / 194 = 0.284 (2016) - Q2 - T1 Categ. JCR: PSYCHOLOGY, EXPERIMENTAL rank: 43 / 142 = 0.303 (2016) - Q2 - T1 Factor impacto SCIMAGO: 2.016 - Psychiatry and Mental Health (Q1) - Clinical Psychology (Q1)